In TMZ-sensitive and TMZ-resistant human glioma cells, PAMs inhibited MAO-A catalytic activity and decreased glioma cell growth, colony formation, and cell migration, while in an in vivo mouse glioblastoma model, this treatment limited tumor growth and increased the survival rate. This evidence concerns the gene MAOA and neoplasm.